Cargando…

Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer

Background. Assessment of DNA methylation of specific genes is one approach to the diagnosis of cancer worldwide. Early stage detection is necessary to reduce the mortality rate of cancers, including those occurring in the stomach. For this purpose, tumor cells in circulating blood offer promising c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimson, Charinya, Ekalaksananan, Tipaya, Pientong, Chamsai, Promthet, Supannee, Putthanachote, Nuntiput, Suwanrungruang, Krittika, Wiangnon, Surapon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906662/
https://www.ncbi.nlm.nih.gov/pubmed/27330867
http://dx.doi.org/10.7717/peerj.2112
_version_ 1782437448277557248
author Pimson, Charinya
Ekalaksananan, Tipaya
Pientong, Chamsai
Promthet, Supannee
Putthanachote, Nuntiput
Suwanrungruang, Krittika
Wiangnon, Surapon
author_facet Pimson, Charinya
Ekalaksananan, Tipaya
Pientong, Chamsai
Promthet, Supannee
Putthanachote, Nuntiput
Suwanrungruang, Krittika
Wiangnon, Surapon
author_sort Pimson, Charinya
collection PubMed
description Background. Assessment of DNA methylation of specific genes is one approach to the diagnosis of cancer worldwide. Early stage detection is necessary to reduce the mortality rate of cancers, including those occurring in the stomach. For this purpose, tumor cells in circulating blood offer promising candidates for non-invasive diagnosis. Transcriptional inactivation of tumor suppressor genes, like PCDH10 and RASSF1A, by methylation is associated with progression of gastric cancer, and such methylation can therefore be utilized as a biomarker. Methods. The present research was conducted to evaluate DNA methylation in these two genes using blood samples of gastric cancer cases. Clinicopathological data were also analyzed and cumulative survival rates generated for comparison. Results. High frequencies of PCDH10 and RASSF1A methylations in the gastric cancer group were noted (94.1% and 83.2%, respectively, as compared to 2.97% and 5.45% in 202 matched controls). Most patients (53.4%) were in severe stage of the disease, with a median survival time of 8.4 months after diagnosis. Likewise, the patients with metastases, or RASSF1A and PCDH10 methylations, had median survival times of 7.3, 7.8, and 8.4 months, respectively. A Kaplan–Meier analysis showed that cumulative survival was significantly lower in those cases positive for methylation of RASSF1A than in their negative counterparts. Similarly, whereas almost 100% of patients positive for PCDH10 methylation had died after five years, none of the negative cases died over this period. Notably, the methylations of RASSF1A and PCDH10 were found to be higher in the late-stage patients and were also significantly correlated with metastasis and histology. Conclusions. PCDH10 and RASSF1A methylations in blood samples can serve as potential non-invasive diagnostic indicators in blood for gastric cancer. In addition to RASSF1A methylation, tumor stage proved to be a major prognostic factor in terms of survival rates.
format Online
Article
Text
id pubmed-4906662
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-49066622016-06-17 Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer Pimson, Charinya Ekalaksananan, Tipaya Pientong, Chamsai Promthet, Supannee Putthanachote, Nuntiput Suwanrungruang, Krittika Wiangnon, Surapon PeerJ Molecular Biology Background. Assessment of DNA methylation of specific genes is one approach to the diagnosis of cancer worldwide. Early stage detection is necessary to reduce the mortality rate of cancers, including those occurring in the stomach. For this purpose, tumor cells in circulating blood offer promising candidates for non-invasive diagnosis. Transcriptional inactivation of tumor suppressor genes, like PCDH10 and RASSF1A, by methylation is associated with progression of gastric cancer, and such methylation can therefore be utilized as a biomarker. Methods. The present research was conducted to evaluate DNA methylation in these two genes using blood samples of gastric cancer cases. Clinicopathological data were also analyzed and cumulative survival rates generated for comparison. Results. High frequencies of PCDH10 and RASSF1A methylations in the gastric cancer group were noted (94.1% and 83.2%, respectively, as compared to 2.97% and 5.45% in 202 matched controls). Most patients (53.4%) were in severe stage of the disease, with a median survival time of 8.4 months after diagnosis. Likewise, the patients with metastases, or RASSF1A and PCDH10 methylations, had median survival times of 7.3, 7.8, and 8.4 months, respectively. A Kaplan–Meier analysis showed that cumulative survival was significantly lower in those cases positive for methylation of RASSF1A than in their negative counterparts. Similarly, whereas almost 100% of patients positive for PCDH10 methylation had died after five years, none of the negative cases died over this period. Notably, the methylations of RASSF1A and PCDH10 were found to be higher in the late-stage patients and were also significantly correlated with metastasis and histology. Conclusions. PCDH10 and RASSF1A methylations in blood samples can serve as potential non-invasive diagnostic indicators in blood for gastric cancer. In addition to RASSF1A methylation, tumor stage proved to be a major prognostic factor in terms of survival rates. PeerJ Inc. 2016-06-09 /pmc/articles/PMC4906662/ /pubmed/27330867 http://dx.doi.org/10.7717/peerj.2112 Text en ©2016 Pimson et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Molecular Biology
Pimson, Charinya
Ekalaksananan, Tipaya
Pientong, Chamsai
Promthet, Supannee
Putthanachote, Nuntiput
Suwanrungruang, Krittika
Wiangnon, Surapon
Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
title Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
title_full Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
title_fullStr Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
title_full_unstemmed Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
title_short Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
title_sort aberrant methylation of pcdh10 and rassf1a genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
topic Molecular Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906662/
https://www.ncbi.nlm.nih.gov/pubmed/27330867
http://dx.doi.org/10.7717/peerj.2112
work_keys_str_mv AT pimsoncharinya aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer
AT ekalaksananantipaya aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer
AT pientongchamsai aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer
AT promthetsupannee aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer
AT putthanachotenuntiput aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer
AT suwanrungruangkrittika aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer
AT wiangnonsurapon aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer